Zim Labs secures TGA GMP cert for Nagpur facility
- Zim Laboratories received TGA GMP certification for its Nagpur facility on October 15, 2026
- Certification covers soluble films, wafers, tablets, capsules, and granules
- Valid until June 21, 2028, supporting Australian market entry and RoW regulatory submissions
*this image is generated using AI for illustrative purposes only.
Zim Laboratories Limited received a Certificate of Good Manufacturing Practice (GMP) Compliance from Australia’s Therapeutic Goods Administration (TGA) for its manufacturing facility in Nagpur, Maharashtra. The certification, issued on October 15, 2026, validates the plant’s adherence to international quality standards for multiple dosage forms.
The approval follows an on-site inspection conducted on April 18 and April 20–21, 2026. It confirms compliance with the PIC/S Guide to Good Manufacturing Practice for Medicinal Products dated August 25, 2023. This regulatory milestone supports the company’s efforts to develop manufacturing partnerships and pursue opportunities in the Australian market, subject to product-specific approvals.
Scope of certification
The certificate covers the manufacture of non-sterile finished products across both registered and listed therapeutic goods categories. The specific dosage forms included in the scope are:
- Hard capsules
- Solid unit dosage forms
- Tablets
- Granules
- Powders for suspension
- Wafers
- Soluble films
The breadth of these certified forms provides a foundation for engaging with partners across a range of pharmaceutical product requirements. The certification is valid until June 21, 2028, subject to scheduled re-inspections by the TGA. No further conditions apply to the manufacturing operations covered under this certificate.
Strategic implications
Beyond direct access to Australia, the TGA GMP certification strengthens Zim’s credentials in Rest of World (RoW) markets. It serves as supporting GMP evidence for regulatory submissions in countries that accept or rely on TGA inspection outcomes, subject to each jurisdiction’s specific requirements. This dual utility enhances the company’s regulatory efficiency across multiple geographies.
What the numbers show
The timeline from inspection (April 2026) to certification (October 2026) reflects a six-month review period, typical for rigorous international audits. The inclusion of niche formats like soluble films and wafers alongside standard tablets indicates a diversified manufacturing capability that extends beyond conventional generics, potentially reducing dependency on high-volume, low-margin segments.
Historical Stock Returns for Zim Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.41% | +3.24% | +8.59% | +90.31% | +107.12% | +29.39% |
Which specific Australian pharmaceutical partners or distributors is Zim Laboratories currently in advanced negotiations with following this TGA GMP certification?
How does the inclusion of niche dosage forms like soluble films and wafers in the certification scope position Zim to capture higher-margin market segments compared to traditional generics?
What are the projected revenue contributions from the Australian market and other RoW regions that accept TGA standards within the next 12 to 24 months?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
